Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
3期
已完成
NCT03260894
| 适应症 | Renal Cell Carcinoma |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Incyte Corporation |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 129 人 |
|---|
| 干预（药物） | Pembrolizumab, Epacadostat, Sunitinib, Pazopanib |
|---|
| 开始日期 | 2017年12月7日 |
|---|
| 完成日期 | 2018年8月22日 |
|---|
| 结果公布日 | 2019年9月10日 |
|---|
摘要
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.
Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC)
up to approximately 8 months · percentage of participants
| Pembrolizumab + Epacadostat | 1.6 percentage of participants |
|---|
| SoC (Sunitinib or Pazopanib) | 0.0 percentage of participants |
|---|
| Pembrolizumab + Epacadostat | 29.7 percentage of participants |
|---|
| SoC (Sunitinib or Pazopanib) | 29.2 percentage of participants |
|---|
| Pembrolizumab + Epacadostat | 31.3 percentage of participants |
|---|
| SoC (Sunitinib or Pazopanib) | 29.2 percentage of participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。